Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Feb 2019 · 1 min read
In brief
In brief
Retrospective study examining whether preoperative anti-TNF biologic therapy increases 30-day postoperative infectious complications in pediatric Crohn's disease patients undergoing abdominal surgery. Findings suggest biologic therapy within 12 weeks of operation does not significantly elevate surgical morbidity risk in this population.
Written by the GCMD Library team from the article.
Introduction
Limited knowledge exists as to what impact preoperative biologic therapy has on postoperative complications in pediatric patients undergoing abdominal surgery for Crohn's disease (CD). Therefore, we sought to determine the 30-day postoperative infectious complication rate among pediatric CD patients who received biologic therapy within 12 weeks of an abdominal operation.
Methods
A retrospective chart review was performed on pediatric (